FDA Approves BOSENTAN — Lupin Pharmaceuticals, Inc.

# FDA Approves Generic Bosentan; Lupin Pharmaceuticals Enters Pulmonary Hypertension Market Lupin Pharmaceuticals, Inc. has received FDA approval for generic bosentan oral tablets under ANDA 213154, enabling the company to compete in the pulmonary arterial hypertension treatment market and potentially capturing market share from branded alternatives. The approval is expected to increase price competition and improve patient access to this endothelin receptor antagonist therapy.